Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial
Désirée van der Heijde, Xenofon Baraliakos, Joachim Sieper, Atul Deodhar, Robert D. Inman, Hideto Kameda, Xiaofeng Zeng, Yunxia Sui, Xianwei Bu, Aileen L. Pangan, Peter Wung, In‐Ho Song
Topics & Concepts
MedicineAnkylosing spondylitisPlaceboClinical endpointInternal medicineAdverse effectBASDAITolerabilitySpondylitisRandomized controlled trialArthritisPsoriatic arthritisPathologyAlternative medicineSpondyloarthritis Studies and TreatmentsRheumatoid Arthritis Research and TherapiesSpine and Intervertebral Disc Pathology